| CTNT 0.1608 -5.80% | ZSPC 0.0871 21.48% | ONFO 1.5 124.89% | MYSE 3.3 129.17% | NVDA 198.35 -0.26% | BITO 10.35 0.49% | TZA 5.43 -0.46% | TSLL 13.07 -1.73% | INTC 68.5 5.48% | CAPS 0.5345 -9.25% | HUBC 0.1833 -29.50% | DVLT 0.8375 19.63% | SOXS 20.28 -3.13% | TQQQ 56.43 1.40% | QBTS 21.505 3.34% | AGAE 0.5219 10.57% | HIMS 26.99 11.12% | IONQ 44.68 3.31% | DGNX 0.5556 -0.79% | GRAB 4.02 2.55% | SNAP 6.02 -0.33% | SOFI 19.03 1.28% | SMR 11.41 -2.56% | TSLA 388.9 -0.78% | ITP 0.2 -3.57% | BMNG 1.53 0.66% | SOXL 88.37 2.80% | AMD 278.26 7.80% | RGTI 19.45 1.78% | OPEN 5.27 9.34% | MDCX 0.3003 -0.60% | PLUG 2.86 -2.39% | MARA 11.55 10.32% | NVD 5.81 0.69% | AAL 12.27 0.82% | SQQQ 58.61 -1.40% | IMMP 0.5796 6.54% | HOOD 86.85 -0.54% | ONDS 10.2 1.69% | NVTS 12.37 20.57% | RMSG 2.55 42.46% | BYND 0.782 4.11% | NOK 10.29 3.00% | NFLX 107.79 0.07% | ORCL 178.46 5.09% | SPY 701.66 0.25% | SOUN 7.7 -1.91% | AAPL 263.4 -1.14% | PBM 5.87 103.82% | PLTR 142.76 0.43%

JPMorgan Upgrades Kodiak Sciences To Neutral, Sees Catalyst-Heavy Period Ahead

JPMorgan upgraded Kodiak Sciences (NASDAQ:KOD) from Underweight to Neutral and set a December 2026 price target of $15.00.

The bank said Kodiak is entering a catalyst-rich period over the next two years, with pivotal trial data expected for tarcocimab, KSI-501, and KSI-101. While acknowledging that valuation is not a barrier to a more positive stance, JPMorgan noted that investor sentiment remains mixed and that clear clinical wins may be required to shift views more favorably.

The firm sees Kodiak shares performing in line with the broader biotech sector until further clarity emerges from these upcoming data releases.

Published on: August 14, 2025